229 related articles for article (PubMed ID: 28755188)
1. Liver Cancer in Tyrosinemia Type 1.
van Ginkel WG; Pennings JP; van Spronsen FJ
Adv Exp Med Biol; 2017; 959():101-109. PubMed ID: 28755188
[TBL] [Abstract][Full Text] [Related]
2. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
Koelink CJ; van Hasselt P; van der Ploeg A; van den Heuvel-Eibrink MM; Wijburg FA; Bijleveld CM; van Spronsen FJ
Mol Genet Metab; 2006 Dec; 89(4):310-5. PubMed ID: 17008115
[TBL] [Abstract][Full Text] [Related]
3. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
Nobili V; Jenkner A; Francalanci P; Castellano A; Holme E; Callea F; Dionisi-Vici C
Pediatrics; 2010 Jul; 126(1):e235-8. PubMed ID: 20547648
[TBL] [Abstract][Full Text] [Related]
4. The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
Halac U; Dubois J; Mitchell GA
Adv Exp Med Biol; 2017; 959():75-83. PubMed ID: 28755185
[TBL] [Abstract][Full Text] [Related]
5. HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1.
Seda Neto J; Leite KM; Porta A; Fonseca EA; Feier FH; Pugliese R; Miura IK; Chapchap P; Porta G
Pediatr Blood Cancer; 2014 Sep; 61(9):1584-9. PubMed ID: 24852359
[TBL] [Abstract][Full Text] [Related]
6. [Evolution of a case of tyrosinemia type I treated with NTBC].
Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP.
van Ginkel WG; Gouw AS; van der Jagt EJ; de Jong KP; Verkade HJ; van Spronsen FJ
Pediatrics; 2015 Mar; 135(3):e749-52. PubMed ID: 25667247
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment.
van Spronsen FJ; Bijleveld CM; van Maldegem BT; Wijburg FA
J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):90-3. PubMed ID: 15625434
[No Abstract] [Full Text] [Related]
9. [Lectin-reactive alpha-fetoprotein in tyrosinaemia type I].
Baumann U; Duhme V; Knerr I; Pronicka E; Auth MK; Voit PT
Klin Padiatr; 2005; 217(3):142-6. PubMed ID: 15858705
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G; Tanguay RM
Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
[TBL] [Abstract][Full Text] [Related]
11. Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients.
van Ginkel WG; Jahja R; Huijbregts SCJ; van Spronsen FJ
Adv Exp Med Biol; 2017; 959():111-122. PubMed ID: 28755189
[TBL] [Abstract][Full Text] [Related]
12. Hereditary Tyrosinemia Type 1 in Turkey.
Aktuglu-Zeybek AC; Kiykim E; Cansever MS
Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
[TBL] [Abstract][Full Text] [Related]
13. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
Crone J; Möslinger D; Bodamer OA; Schima W; Huber WD; Holme E; Stöckler Ipsiroglu S
Acta Paediatr; 2003 May; 92(5):625-8. PubMed ID: 12839296
[TBL] [Abstract][Full Text] [Related]
14. The outcome of seven patients with hereditary tyrosinemia type 1.
Gokay S; Ustkoyuncu PS; Kardas F; Kendirci M
J Pediatr Endocrinol Metab; 2016 Oct; 29(10):1151-1157. PubMed ID: 27682708
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.
Bhushan S; Noble C; Balouch F; Lewindon P; Lampe G; Hodgkinson P; McGill J; Ee L
Pediatr Transplant; 2022 Nov; 26(7):e14334. PubMed ID: 35698261
[TBL] [Abstract][Full Text] [Related]
16. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
Raimann E; Cornejo V; Arias C; Cabello JF; Castro G; Fernández E; de la Parra A
Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
[TBL] [Abstract][Full Text] [Related]
17. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.
Orejuela D; Jorquera R; Bergeron A; Finegold MJ; Tanguay RM
J Hepatol; 2008 Feb; 48(2):308-17. PubMed ID: 18093685
[TBL] [Abstract][Full Text] [Related]
18. Lectin-reactive alpha-fetoprotein in patients with tyrosinemia type I and hepatocellular carcinoma.
Baumann U; Duhme V; Auth MK; McKiernan PJ; Holme E
J Pediatr Gastroenterol Nutr; 2006 Jul; 43(1):77-82. PubMed ID: 16819381
[TBL] [Abstract][Full Text] [Related]
19. Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype.
Neuckermans J; Lequeue S; Claes P; Heymans A; Hughes JH; Colemonts-Vroninks H; Marcélis L; Casimir G; Goyens P; Martens GA; Gallagher JA; Vanhaecke T; Bou-Gharios G; De Kock J
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980965
[TBL] [Abstract][Full Text] [Related]
20. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
